77 related articles for article (PubMed ID: 19835827)
1. Identification of potent biodegradable adjuvants that efficiently break self-tolerance--a key issue in the development of therapeutic vaccines.
Ringvall M; Huijbers EJ; Ahooghalandari P; Alekseeva L; Andronova T; Olsson AK; Hellman L
Vaccine; 2009 Dec; 28(1):48-52. PubMed ID: 19835827
[TBL] [Abstract][Full Text] [Related]
2. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine.
Johansson J; Hellman L
Vaccine; 2007 Feb; 25(9):1676-82. PubMed ID: 17150285
[TBL] [Abstract][Full Text] [Related]
3. Identification of adjuvants that enhance the therapeutic antibody response to host IgE.
Johansson J; Ledin A; Vernersson M; Lövgren-Bengtsson K; Hellman L
Vaccine; 2004 Jul; 22(21-22):2873-80. PubMed ID: 15246623
[TBL] [Abstract][Full Text] [Related]
4. Montanide ISA 71 VG is Advantageous to Freund's Adjuvant in Immunization Against S. aureus Infection of Mice.
Klimka A; Michels L; Glowalla E; Tosetti B; Krönke M; Krut O
Scand J Immunol; 2015 May; 81(5):291-7. PubMed ID: 25689117
[TBL] [Abstract][Full Text] [Related]
5. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits.
Halassy B; Vdović V; Habjanec L; Balija ML; Gebauer B; Sabioncello A; Santek T; Tomasić J
Vaccine; 2007 Apr; 25(17):3475-81. PubMed ID: 17239503
[TBL] [Abstract][Full Text] [Related]
7. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B--a prerequisite for clinical development.
Huijbers EJ; Femel J; Andersson K; Björkelund H; Hellman L; Olsson AK
Vaccine; 2012 Jan; 30(2):225-30. PubMed ID: 22079080
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA
Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
Habjanec L; Halassy B; Tomasić J
Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
[TBL] [Abstract][Full Text] [Related]
10. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom.
Waghmare A; Deopurkar RL; Salvi N; Khadilkar M; Kalolikar M; Gade SK
Vaccine; 2009 Feb; 27(7):1067-72. PubMed ID: 19100805
[TBL] [Abstract][Full Text] [Related]
12. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the Plasmodium falciparum Pf332-DBL domain in combination with different adjuvants.
Du C; Nilsson S; Lu H; Yin J; Jiang N; Wahlgren M; Chen Q
Vaccine; 2010 Jul; 28(31):4977-83. PubMed ID: 20653104
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
15. Comparison of mouse and rabbit model for the assessment of strong PGM-containing oil-based adjuvants.
Habjanec L; Halassy B; Vdović V; Balija ML; Tomasić J
Vet Immunol Immunopathol; 2008 Feb; 121(3-4):232-40. PubMed ID: 17996307
[TBL] [Abstract][Full Text] [Related]
16. Effect of different adjuvants in equines for the production of equine rabies immunoglobulin.
Arora S; Sharma S; Goel SK; Singh US
Natl Med J India; 2005; 18(6):289-92. PubMed ID: 16483026
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immune and adverse effects induced by AdjuVac and Freund's complete adjuvant in New Zealand white rabbits (Oryctolagus cuniculus).
Powers JG; Nash PB; Rhyan JC; Yoder CA; Miller LA
Lab Anim (NY); 2007 Oct; 36(9):51-8. PubMed ID: 17885664
[TBL] [Abstract][Full Text] [Related]
18. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex.
Jones DE; Palmer JM; Burt AD; Walker C; Robe AJ; Kirby JA
Hepatology; 2002 Sep; 36(3):679-86. PubMed ID: 12198661
[TBL] [Abstract][Full Text] [Related]
19. Studies on the efficacy of different adjuvants in live stock specific bacterial vaccines for turkeys against Bordetella infection and onset of antibody titers in respect to the age of the turkey poults.
Glünder G; van der Ven H; Foulman A
Pol J Vet Sci; 2004; 7(2):77-81. PubMed ID: 15230536
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
